Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-09-21
2001-07-17
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S300000, C514S311000
Reexamination Certificate
active
06262071
ABSTRACT:
This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against Mycoplasma bacteria, such as
Mycolplasma pneumoniae.
BACKGROUND OF THE INVENTION
Quinolones have been shown to be effective to varying degrees against a range of bacterial pathogens. However, as diseases caused by these pathogens are on the rise, there exists a need for antimicrobial compounds that are more potent than the present group of quinolones.
Gemifloxacin mesylate (SB-265805) is a novel fluoroquinolone useful as a potent antibacterial agent. Gemifloxacin compounds are described in detail in patent application PCT/KR98/00051 published as WO 98/42705. Patent application EP 688772 discloses novel quinoline(naphthyridine)carboxylic acid derivatives, including anhydrous (R,S)-7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid of formula I.
PCT/KR98/00051 discloses (R,S)-7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof including the sesquihydrate.
Provided herein is a significant discovery made using a gemifloxacin compound against Mycoplasma, demonstrating the activity of the gemifloxacin compound used was superior to a number of quinolones as described in more detail herein. Germifloxacin compounds are valuable compounds for the treatment of bacterial infection caused by a range of Mycoplasma pathogens, including those resistant to usual oral therapy, thereby filling an unmet medical need.
SUMMARY OF THE INVENTION
An object of the invention is a method for modulating metabolism of pathogenic Mycoplasma bacteria comprising the step of contacting pathogenic Mycoplasma bacteria with an antibacterially effective amount of a composition comprising a quinolone, particularly a gemifloxacin compound, or an antibacterially effective derivative thereof.
A further object of the invention is a method wherein said pathogenic Mycoplasma bacteria is selected from the group consisting of:
Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitaliun, M. penetrans
and
Ureaplasma urealyticum.
Also provided by the invention is a method of treating or preventing a bacterial infection by pathogenic Mycoplasma bacteria comprising the step of administering an antibacterially effective amount of a composition comprising a quinolone, particularly a gemifloxacin compound to a mammal suspected of having or being at risk of having an infection with pathogenic Mycoplasma bacteria.
A preferred method is provided wherein said modulating metabolism is inhibiting growth of said bacteria or killing said bacteria.
A further preferred method is provided wherein said contacting said bacteria comprises the further step of introducing said composition into a mammal, particularly a human.
Further preferred methods are provided by the invention wherein said bacteria is selected from the group consisting of:
Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitalium, M. penetrans
and
Ureaplasma urealyticum.
Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.
REFERENCES:
patent: 5776944 (1998-07-01), Hong et al.
patent: 5962468 (1999-10-01), Hong et al.
patent: 0 688 772 A1 (1995-12-01), None
patent: WO 98/42705 (1998-10-01), None
Crabb Donna M.
Duffy Lynn B.
Searcy Karen B.
Gimmi Edward R.
Henderson Loretta J.
Kinzig Charles M.
SmithKline Beecham Corporation
Weddington Kevin E.
LandOfFree
Methods of use of antimicrobial compounds against pathogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of use of antimicrobial compounds against pathogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of use of antimicrobial compounds against pathogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2527977